RESUMO
BACKGROUND AND PURPOSE: To prospectively evaluate long-term urinary, bowel and sexual function after I-125 brachytherapy for localised prostate cancer using patient administered validated Quality of Life (QoL) instruments. MATERIALS AND METHODS: Between March 1995 and March 2004, 673 men underwent brachytherapy and recorded urinary symptoms prospectively using the International Prostate Symptom Score (IPSS). In addition, in a subgroup of 116 patients, the Expanded Prostate Cancer Index Composite (EPIC) was used to record QoL information on urinary, bowel and sexual function before treatment and at regular time intervals for at least two years. RESULTS: Initially, there was a sharp rise in urinary symptoms which was most marked within the first three months. Scores then resolved slowly and returned to within one or two units of pre-treatment level at one year. Subsequently, there was no significant deterioration in urinary symptoms up to nine years following brachytherapy. Few had significant bowel symptoms. Sexual function deteriorated initially and then improved but failed to return to pre-treatment levels by two years. Patients requiring neo-adjuvant hormones experienced significantly more dysfunction. CONCLUSIONS: After an initial period of mild to moderate urinary symptoms prostate brachytherapy is well tolerated with relatively little deterioration in long-term quality of life. Long-term reduction in sexual function may be seen particularly in those requiring hormones.
Assuntos
Braquiterapia , Neoplasias da Próstata/radioterapia , Qualidade de Vida , Terapia de Reposição Hormonal , Humanos , Enteropatias/etiologia , Masculino , Terapia Neoadjuvante , Estudos Prospectivos , Disfunções Sexuais Fisiológicas/etiologia , Inquéritos e Questionários , Doenças Urológicas/etiologiaRESUMO
PURPOSE: To report the side effects and complications after I-125 seeds prostate implant after 8.5 years experience. METHODS AND MATERIALS: Six hundred and sixty seven (667) patients were treated between March 1995 and December 2001. The median follow up is 31 months with a maximum of 98.2 months. Morbidity data were collected from a review of patient case-notes. Patients also provided prospective data on urinary symptoms using the International Prostate Symptom Score (IPSS) scoring chart before treatment and at regular follow up. Patients were also sent a questionnaire detailing symptoms and side effects following their brachytherapy. This enabled them to record urinary, bowel and sexual function side effects independently. Logistic regression analysis was carried out to identify the risk of catheterisation in relation to the pre-implant prostate volume and potential implant factors such as the number of seeds and needles and implant dose. RESULT: The urinary symptom score rises in the first few months after implantation and returns to within one or two points of the pre-treatment score within one year. Nine patients reported incontinence prior to treatment and 15, 12 and 10 patients reported incontinence 6, 12 and 24 months after treatment, respectively. Catheterisation was reported in 97 (14.5%) patients. At six months 84.9% of patients reported no change in bowel function and 78.9% at 12 months. 6.4% of patients complained of some increased bowel frequency at 6 months and 5.7% at 12 months. 402 (77.2%) patients reported being fully potent before treatment and that this fell to 32.4% after treatment. Logistic regression showed that the most significant factors which correlate with the probability of catheterisation are the pre-treatment prostate volume and the number of seeds and needles implanted. CONCLUSION: The side effects and complications after prostate brachytherapy as reported here and elsewhere confirm that the treatment is not only convenient but also has a low risk of serious long term side effects.
Assuntos
Braquiterapia/métodos , Radioisótopos do Iodo/efeitos adversos , Neoplasias da Próstata/radioterapia , Adolescente , Adulto , Idoso , Disfunção Erétil/epidemiologia , Disfunção Erétil/etiologia , Humanos , Radioisótopos do Iodo/uso terapêutico , Modelos Logísticos , Masculino , Dosagem Radioterapêutica , Risco , Uretrite/epidemiologia , Uretrite/etiologia , Incontinência Urinária/epidemiologia , Incontinência Urinária/etiologia , Retenção Urinária/epidemiologia , Retenção Urinária/etiologiaRESUMO
BACKGROUND AND PURPOSE: In 1998 Stock and Stone demonstrated a dose response relationship correlating D90 with probability of biochemical control and showed that a D90 of 140 Gy is a highly significant factor in predicting PSA relapse free survival (PSA-RFS). Although, a mean D90 of over 140 Gy was achieved in our series, there is nevertheless a normal distribution with 20% of patients achieving a D90 of less than 120 Gy. We have analysed the possible causes for the low D90 and the impact on outcome. PATIENTS AND METHODS: Prospective data from 667 patients treated between 1995 and 2001 by I-125 seeds prostate implant as monotherapy were analysed. Post-implant dosimetry was performed on 413 patients. D90 and other indices were calculated for each patient. Statistical analysis was performed on D90 dose to identify the correlation that would predict the 8.2 years PSA relapse free survival as defined by the American Society for Therapeutic Radiology and Oncology (ASTRO). RESULTS: Correlation between D90 and outcome shows no significant difference for the whole population between those who receive greater or less than 140 Gy (P=0.43) and there was also no difference for those receiving more or less than 130 Gy (P=0.14). Subgroup analysis by risk group, however, showed that for low risk patients there was a significant correlation between D90 and PSA control (P<0.01). Although, post-implant dosimetry was performed 6-8 weeks after brachytherapy, post-implant CT still showed variable levels of oedema compared with the pre-implant ultrasound. A statistically significant relationship was shown between D90 and the ratio between CT and ultrasound volume (P<0.01) which suggests that some low D90s may be related to persistent oedema at the time of calculation. Segmental analysis of a subgroup of 32 patients showed that the dose was most often deficient in the anterior basal segment of the gland. CONCLUSIONS: D90 was found to be a good discriminator for those with low risk where failure to achieve local control is likely to be the dominant cause of PSA failure. No significant dose response relationship between D90 and PSA was found in the intermediate and high-risk population of patients. This could be due to (1) the presence of oedema or discrepancy between pre- and post-implant volumes causing a low D90, (2) the possibility that the underdosed area could be situated where there is unlikely to be tumour, (3) the fact that biochemical control does not equate to local control because some patients fail outside the prostate, particularly in the high and intermediate risk patients, (4) if D90 is a good discriminator only for low risk patients, the absence of a dose response correlation in this series which contained 53.8% intermediate and high risk patients could be related to case mix.
Assuntos
Braquiterapia , Neoplasias da Próstata/radioterapia , Relação Dose-Resposta à Radiação , Humanos , Radioisótopos do Iodo/uso terapêutico , Masculino , Estudos Prospectivos , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/sangue , Neoplasias da Próstata/mortalidade , Resultado do TratamentoRESUMO
BACKGROUND AND PURPOSE: Many patients with localised prostate cancer present with symptoms of benign prostatic hypertrophy (BPH) and require neoadjuvant hormone therapy to shrink the gland before brachytherapy. The impact of this hormone therapy has been evaluated in 667 patients treated with Iodine seed monotherapy. PATIENTS AND METHODS: Prospective data from 667 patients treated between 1995 and 2001 by I-125 seeds prostate implant as monotherapy were analysed. The mean age was 63 years (42--77 years). Three hundred and forty-six (51.9%) patients had a short course of neo adjuvant hormone therapy and 321 (49.1%) did not. The prescribed minimum peripheral dose was 145 Gy (TG 43). Patients were followed up to a maximum of 8.2 years and a minimum of 18 months. Statistical analysis was performed to identify factors that would predict PSA relapse-free survival (PSA-RFS) defined by the American Society for Therapeutic Radiology and Oncology (ASTRO). RESULTS: Overall the PSA relapse-free survival is 76.1 and 72.6% for patient cohorts being on pre-treatment hormones and not, respectively (P=0.107). Subdivided into risk groups the low risk group showed 92.5% PSA-RFS with hormones and 75.1% without (P=0.327). The intermediate group 75.7% with hormones and 72.9% without (P=0.148) and for the high-risk group 51.1% with and 51.1% without hormones (P=0.942). Evaluation of post-implant dosimetry in patients with and without hormone therapy showed that the D90 for those who received hormone therapy was 130.8 Gy compared with 145.1 Gy for those who did not (P<0.001). This may be related to the degree of oedema at the time of post-implant dosimetry. The CT to ultrasound prostate volume ratio was 1.17 for patients who received hormone therapy and 0.98 for those who did not (P<0.001). It is suggested that in the interval between stopping hormone therapy and doing post-implant dosimetry there was an increase in prostate volume, which results in a lower D90. Significant correlation was found between D90 and prostate volume on post-implant CT dosimetry with higher D90s for small volume prostates (P<0.001). CONCLUSIONS: Overall hormone therapy had no significant effect on outcome. The apparent lower D90 in hormone treated patients may be related to a change in volume between pre-implant and post-implant dosimetry.
Assuntos
Anilidas/uso terapêutico , Braquiterapia , Gosserrelina/uso terapêutico , Radioisótopos do Iodo/uso terapêutico , Neoplasias da Próstata/radioterapia , Dosagem Radioterapêutica , Adulto , Idoso , Humanos , Masculino , Pessoa de Meia-Idade , Nitrilas , Estudos Prospectivos , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/mortalidade , Neoplasias da Próstata/patologia , Compostos de TosilRESUMO
PURPOSE: A number of reports of (125)I seed migration to the lungs after prostate brachytherapy have been published. There are, however, very limited data available on how to reduce the risk of this event. The purpose of the present report is to determine whether seed embolization to the lungs can be minimized by using stranded seeds alone for brachytherapy. METHODS AND MATERIALS: Between December 2001 and December 2002, 238 patients with early prostate cancer were treated with prostate brachytherapy as monotherapy using (125)I stranded seeds (RAPIDStrand) exclusively. All patients had fluoroscopy during the implant and immediate postimplant radiographs of the pelvis. A sample of 100 patients had chest radiographs performed, on average, 55 days after implant. To determine the ease, or lack of ease, with which these (125)I seeds could be visualized, 4 patients who did not have prostate cancer and who were having routine chest radiographs as part of their management for other cancers consented to have posteroanterior and lateral radiographs performed with inactive (125)I seeds taped to the skin of the thorax. All radiographs were reviewed by a single radiologist. RESULTS: The number of seeds noted on the postimplant radiographs corresponded to the number of implanted seeds in all 238 cases: There was, therefore, no evidence of seed embolization immediately postimplant. On review of the 100 chest radiographs, no embolized seeds were found. CONCLUSION: No evidence of seed embolization was observed with the use of stranded (125)I seeds as used for prostate brachytherapy.
Assuntos
Braquiterapia/instrumentação , Neoplasias da Próstata/radioterapia , Embolia Pulmonar/prevenção & controle , Braquiterapia/métodos , Desenho de Equipamento , Humanos , Radioisótopos do Iodo/uso terapêutico , Masculino , Neoplasias da Próstata/diagnóstico por imagem , RadiografiaRESUMO
PURPOSE: An analysis of computed tomography (CT)-based dosimetry was performed to evaluate the variability of different observers' judgements in marking the prostate gland on CT films, and its effect on the parameters that characterise the prostate implantation quality. Accuracy of data entry by the first author in the process of dosimetry procedure has also been evaluated. MATERIALS AND METHODS: Four observers were asked to evaluate the prostate volume on CT films for six different patients. Each observer repeated the evaluation six times. The sample of patients has a prostate volume in the range of 21.4-42.0 cc derived from transrectal ultrasound volume study. After an average period of 6 weeks of the I-125 implantation, all patients had CT scans. CT-based post-implant dosimetry was performed and the dose volume histograms DVHs were calculated to report the re-constructed prostate volume, Vp100, Vp150, Vp90 and D90. Comparison between the four observers' output was performed. RESULTS: Comparison between the four observers shows that each observer has a different way of estimating the prostate on CT films. Observers' precision also varies according to the prostate volume and the image quality. This can cause a variation in the resulting D90 value by up to 50%. Analysis of data entry shows a high degree of accuracy. The error of digitizing the prostate is +/-0.19 cc. This is correlated to an error of +/-0.78 Gy of the D90. CONCLUSION: The evaluation of prostate gland volume on CT films varies between different observers. This has an effect on the dosimetric indices that characterise the implant quality in particular the D90.
Assuntos
Próstata/diagnóstico por imagem , Neoplasias da Próstata/radioterapia , Humanos , Masculino , Variações Dependentes do Observador , Próstata/anatomia & histologia , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador , Tomografia Computadorizada por Raios XRESUMO
PURPOSE: This study reports the 10-year experience of permanent brachytherapy monotherapy at a single UK center. METHODS AND MATERIALS: Between March 1995 and September 2004, 1,298 patients underwent trans-rectal ultrasound (TRUS) planned transperineal brachytherapy delivering 145 Gy using I-125. No patient received supplemental external beam; 44.2% received neoadjuvant hormones. In 688, CT postimplant dosimetry was available. Outcome data were analyzed in terms of overall survival (OS), disease specific survival (DSS), and PSA relapse-free survival (PSA-RFS). RESULTS: The mean age was 62.9 (range, 34-83) years. Median follow-up was 4.9 years (range, 2.03-11.7 years). OS and DSS were 85% and 95%, respectively, at 10 years. Twenty-one patients died from prostate cancer (1.6%) and 34 (2.5%) from unrelated causes. Seventy-four (5.7%) developed evidence of clinical failure. Overall PSA-RFS was 79.9% and 72.1% at 10 years (American Society for Therapeutic Radiology and Oncology [ASTRO] and Nadir+2 definitions, respectively). Higher presenting PSA or Gleason score and use of neoadjuvant hormones were associated with an increased risk of biochemical failure (p <0.01). Biochemical control was achieved in 86.4%, 76.7%, and 60.6% (ASTRO) and 72.3%, 73.5%, and 57.6% (Nadir+2) of patients in low-, intermediate-, and high-risk groups, respectively. Biochemical control was achieved in 88% of patients with D(90) > or =140 Gy and in 78% of patients with D(90) <140 Gy (p <0.01). CONCLUSIONS: I-125 brachytherapy alone achieved excellent rates of medium-term biochemical control in both low- and selected intermediate-risk localized prostate cancer patients. Postimplant dosimetry improved with experience and longer follow-up, confirming the relationship of D(90) with biochemical control.
Assuntos
Braquiterapia/métodos , Radioisótopos do Iodo/uso terapêutico , Neoplasias da Próstata/radioterapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Antagonistas de Androgênios/uso terapêutico , Causas de Morte , Intervalo Livre de Doença , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Modelos de Riscos Proporcionais , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/sangue , Neoplasias da Próstata/mortalidade , Neoplasias da Próstata/patologia , Dosagem Radioterapêutica , Valores de Referência , Resultado do Tratamento , Ultrassonografia de Intervenção/métodosRESUMO
BACKGROUND AND PURPOSE: The effect of predominating Gleason grade (3+4 versus 4+3) in Gleason sum score (GS) 7 prostate cancer (PCa) on brachytherapy outcomes is unclear. The 10 year experience of permanent brachytherapy monotherapy at a single UK centre for GS 7, intermediate risk (Memorial Sloan-Kettering model), PSA < or = 10 ng/ml, localised PCa is reported. MATERIALS AND METHODS: Between 1995 and 2004, the outcomes of 187 patients with GS 7 PCa (PSA < or = 10 ng/ml) were analysed from a cohort of 1298 men treated with permanent Iodine-125 prostate brachytherapy, including PSA relapse-free survival (PSA-RFS). RESULTS: Median follow-up was 5.0 years (range 2.0-10.1 years). One patient has died of PCa. At 10 years, PSA-RFS was 82.4%/78% (ASTRO consensus and nadir +2 definitions). For GS 3+4, 5 year PSA-RFS was 86.7%/87.9% and for GS 4+3: 85.2%/96.6% respectively, with no significant difference between groups. Five year PSA-RFS (ASTRO) of 92.6% was seen for D(90) > or = 140 Gy (50% total), compared with 77.0% below 140 Gy (p=0.08). CONCLUSIONS: Iodine-125 brachytherapy monotherapy achieved good rates of medium term biochemical control in GS 7, intermediate risk localised PCa patients. There was a trend to improved outcomes in men with a D90 in excess of 140 Gy.